ArticleEuropean journal of nuclear medicine and molecular imaging2022

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.

Philipp E Hartrampf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.